Real-world Evidence of Improved Patient Outcomes With Reslizumab in Non-exacerbating Patients With Severe Eosinophilic Asthma (SEA): A Subgroup Analysis

被引：0
|
作者：
Peters, Stephen [1 ]
Wechsler, Michael [2 ]
Chipps, Bradley [3 ]
Hill, Tanisha [4 ]
Ariely, Rinat [4 ]
Depietro, Michael [4 ]
Terasawa, Emi [5 ]
Thomason, Darren [5 ]
Panettieri, Reynold [6 ]
机构：
[1] Wake Forest Sch Med, Winston Salem, NC 27101 USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA
[4] Teva Branded Pharmaceut R&D Inc, Malvern, PA USA
[5] Anal Grp Inc, New York, NY USA
[6] Rutgers State Univ, New Brunswick, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
081
引用
收藏
页码：AB27 / AB27
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD EVIDENCE OF IMPROVED PATIENT OUTCOMES WITH RESLIZUMAB IN ADULTS WITH SEVERE EOSINOPHILIC ASTHMA (SEA)
    Wechsler, M.
    Peters, S.
    Chipps, B.
    Hill, T.
    Ariely, R.
    DePietro, M.
    Terasawa, E.
    Thomason, D.
    Panettieri, R.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S40 - S40
  • [2] Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma: A Subgroup Analysis of Patients Receiving Reslizumab for More Than 12 Months
    Wechsler, M.
    Peters, S. P.
    Chipps, B. E.
    Hill, T.
    Ariely, R.
    DePietro, M.
    Driessen, M.
    Terasawa, E.
    Thomason, D.
    Panettieri, R. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
    Subramaniam, Abirami
    Mulligan, Emma
    Lane, Stephen
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [4] Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA): Subgroup Analyses of Patients Using Maintenance Oral Corticosteroids (OCS) Prior to Treatment Initiation
    Panettieri, Reynold
    Wechsler, Michael
    Peters, Stephen
    Chipps, Bradley
    Hill, Tanisha
    Ariely, Rinat
    Depietro, Michael
    Terasawa, Emi
    Thomason, Darren
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB26 - AB26
  • [5] Real-world safety of treatment with mepolizumab and reslizumab in patients with severe eosinophilic asthma
    Ordonez Pinilla, Karen A.
    Moya Camacho, Beatriz
    Fernandez Rodriguez, Consuelo
    Fernandez Crespo, Jesus F.
    Garcia Moguel, Ismael
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB99 - AB99
  • [6] Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers
    Hashimoto, Simone
    Kroes, Johannes A.
    Eger, Katrien A.
    Asam, Pearl F. Mau
    Hofstee, Hendrik B.
    Bendien, Sarah A.
    Braunstahl, Gert Jan
    Broeders, Marielle E. A. C.
    Imming, Leonie M.
    Langeveld, Bas
    Maitland-van der Zee, Anke H.
    Oud, Karen T. M.
    Patberg, Kornelis Wiebe
    Smeenk, Frank W. J. M.
    Romme, Elisabeth A. P. M.
    van Bezouw, Maarten J.
    van de Ven, Marjo J.
    van Veen, Anneke
    van Velzen, Edwin
    van Veen, Ilonka H. P. A. A.
    Weersink, Els J. M.
    Ten Brinke, Anneke
    Sont, Jacob K.
    Bel, Elisabeth H.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (08): : 2099 - +
  • [7] Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - "first initiators" and "switchers"
    Hashimoto, S.
    Kroes, J. A.
    Eger, K.
    Mau-Asam, P.
    Hofstee, H. B.
    Bendien, S. A.
    Braunstahl, G.
    Broeders, M. E.
    Imming, L. M.
    Langeveld, B.
    Maitland-Van der Zee, A. H.
    Oud, K. T.
    Patberg, K. W.
    Smeenk, F. W.
    Romme, E. A.
    Van Bezouw, M. J.
    Van de Ven, M. J.
    Van Veen, A.
    Van Velzen, E.
    Van Veen, I. H.
    Weersink, E. J.
    Ten Brinke, A.
    Sont, J. K.
    Bel, E. H.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [8] Real-World Evidence of Reductions in Health Resource Utilization (HRU) and Improved Efficacy Outcomes Associated with Reslizumab Treatment in Adults with Severe Eosinophilic Asthma (SEA) in the United States
    Wechsler, Michael
    Peters, Stephen
    Chipps, Bradley
    Hill, Tanisha
    Ariely, Rinat
    Depietro, Michael
    Terasawa, Emi
    Thomason, Darren
    Panettieri, Reynold
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB27 - AB27
  • [9] Effectiveness of Reslizumab in Severe Eosinophilic Asthma treatment is maintained at 2 years; a real-world experience.
    Ibrahim, H.
    O'Sullivan, R.
    Casey, D.
    Murphy, J.
    Eustace, J.
    Plant, B. J.
    Murphy, D. M.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 (SUPPL 10) : 264 - 264
  • [10] Real-world clinical outcomes for patients in the UK with severe, atopic eosinophilic asthma treated with benralizumab
    Jackson, D. J.
    Dube, S.
    Morris, T.
    Burhan, H.
    Pfeffer, P.
    [J]. ALLERGY, 2020, 75 : 40 - 40
12345